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Vitamin K Antagonists (VKAs) are widely used in clinical practice and nearly 1% of the entire population receives oral
anticoagulation at least once in life. However, the rate of prescription of anticoagulation is low, compared to what it
should be. No more than 50-60% of patients affected by atrial fibrillation (AF) receive anticoagulation. In the setting of
AF, VKAs are safe and effective when properly managed, reducing stroke and systemic embolism by more than 60%.
VKAs safety and effectiveness are closely related to the quality of anticoagulation (e.g. time in therapeutic range), and
anticoagulation clinics offer the best management of anticoagulant therapy. However, a sizeable proportion of patients
are managed elsewhere. In clinical practice, in the setting of AF, a low prescription rate of VKAs is frequently observed
and this is due also to difficulties in managing laboratory monitoring and drug dose adjustment. The suboptimal
management of therapy with VKAs leads to a lesser efficacy than that reported in clinical trials, and to an increase
in adverse reactions. VKAs still remain the first and only available therapy for a number of diseases (e.g. valvular atrial
fibrillation and mechanical prosthetic heart valves). Now, since approval of the new oral anticoagulants (NOAs), the
choice of anticoagulant therapy in definite settings, such as stroke prevention in non-valvular atrial fibrillation (SPAF)
or treatment of venous thromboembolism, has surely become more intriguing but also more problematic. In light of
these new therapeutic options, we reviewed VKAs therapy, in the setting of atrial fibrillation, focusing on VKAs impact
in real life. We analyzed the data about efficacy and safety of warfarin at three levels: clinical trial and real life, outside
and inside anticoagulation clinics.
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Introduction
Since its unexpected discovery in 1933, warfarin and,
more generally, vitamin K antagonists (VKAs) have
been widely used in clinical practice. Their peculiar
pharmacokinetics and their management induced the
development of professionals and clinics dedicated to
anticoagulation therapy, e.g. the anticoagulation clinics.
A variable proportion of patients treated with VKAs are
managed in anticoagulation clinics, and another sizeable
proportion of patients are managed elsewhere, e.g. general
practitioners, cardiologists, neurologists etc.
The choice of anticoagulant therapy, after approval of
the new oral anticoagulants (NOAs), has surely become
more intriguing but also more problematic. The efficacy* Correspondence: mauro.molteni@aovimercate.org
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distribution, and reproduction in any mediumand safety of warfarin in trials are hardly reproducible in
clinical practice, because of its peculiar characteristics.
When comparing warfarin to something else, this spe-
cific issue should be considered. Therefore, we reviewed
warfarin therapy, focusing on stroke prevention in atrial
fibrillation (SPAF), to describe the discrepancies existing
between clinical trials and real world. We analyzed the
data about efficacy and safety of warfarin at three levels:
that of clinical trial and meta-analyses, to be defined as
ideal, due to the optimal management and patient com-
pliance at that level; that of real life, at the level of dedi-
cated anticoagulation clinics, which involve a very high
accuracy but cannot be extended to the entire popu-
lation of eligible patients; and that of real life, where
patients receiving warfarin are managed by their general
practitioners or other specialists.
We performed our narrative review of literature by
searching publications up to July 2013 in PubMed and
review of relevant reference citations. The key wordsMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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(vitamin K antagonist [Title]) OR (anticoagulation clinic
[Title]) OR (INR [Title]) OR (Time in Therapeutic
Range [Title]) OR (atrial fibrillation [Title]) OR (real
world [Title]) OR (current practice [Title]) OR (dabigatran
[Title]) OR (rivaroxaban [Title]) OR (apixaban [Title]) were
combined to search the database. The additional filters
“controlled clinical trial” “meta-analysis” “review” “abstract
available” “publication dates from 01-01-1988 to 30-06-
2013”, “humans” and ”English language” were applied to
the search results. We retrieved 3178 papers; 2878 were
discarded as not relevant to the review. Of the 300 selected,
271 were not taken into consideration because they were
review articles which were in any case used in searching
reference citations relevant to the topic. Therefore 28 arti-
cles were selected and 20 additional papers were identified
by screening the references of the 300 aforementioned
articles. The present overview has been carried out by
trying to take into account the quality level of men-
tioned studies a number of whom, however, have been
conducted 15 or even 20 years ago and their method-
ology would be today hardly acceptable in the light of
current quality standards.
Efficacy and safety of warfarin in clinical trials and
meta-analysis
Most of the knowledge on the efficacy and safety of war-
farin, in the setting of atrial fibrillation, comes from clin-
ical studies performed almost thirty years ago. Hart’s
meta-analysis [1] outlined warfarin effectiveness, defin-
ing its ability to reduce the incidence of ischemic stroke
and systemic embolism in patients affected by non-
valvular atrial fibrillation. Hart and colleagues reviewed
sixteen trials including nearly 10,000 patients, and
adjusted-dose warfarin was compared both with placebo
and aspirin. In six trials involving nearly 3,000 patients,
oral vitamin K antagonists were compared with placebo
in primary and secondary prevention. The median age of
these patients was 69 and only 20% had experienced a
previous stroke or TIA. The patients assigned to placebo
had a net stroke incidence of 4.6% in primary prevention
and 12.3% in secondary prevention. Warfarin reduced
the incidence of stroke by 59% in the setting of primary
prevention and by 68% in secondary prevention, and ab-
solute risk reduction was respectively 2.7% and 8.4%.
When only ischemic strokes were considered, warfarin
prevented 65% of strokes. As far as bleeding complica-
tions were concerned, warfarin induced twice as many
major bleedings than placebo. Warfarin also induced a
statistically significant all cause mortality reduction: it
was observed a 26% relative risk reduction in mortality
corresponding to a 1.6% absolute reduction. This meta-
analysis also compared VKAs with aspirin alone: five
non-blinded randomized trials were considered, involvingmore than 2,800 patients. Adjusted-dose warfarin was as-
sociated with a 36% relative risk reduction of all strokes;
when only ischemic strokes were considered the relative
risk reduction was 46%. The discrepancy between all stroke
and ischemic stroke risk reduction was largely attribut-
able to the results of the SPAF II study [2] and espe-
cially to the excess of intracranial hemorrhages. In this
study, the target therapeutic range of International
Normalized Ratio (INR) was between 2 and 4.5, which
is now considered as being supra-therapeutic. The inci-
dence of intracranial hemorrhage was more than dou-
bled in this study compared to other trials. When SPAF
II trial was excluded from meta-analysis, the relative
risk reduction for all strokes was 49%. Warfarin in-
duced twice as many intracranial and major extracra-
nial hemorrhages than aspirin and reduced mortality by
a non-significant 8%.
Although methodological features and quality of the
trials varied substantially and often were incompletely
reported, the results of this meta-analysis were con-
firmed by a second meta-analysis, published in 2007 [3].
The same group of Hart and colleagues analyzed several
studies involving about 28,000 patients and produced
similar results to those obtained in the previous decade.
More recently, warfarin effectiveness and safety was
demonstrated through direct comparison to anti-platelet
therapy. The Active W Study [4] enrolled nearly 7,000
patients with AF who were randomized to adjusted-dose
warfarin or to the combination of aspirin and clopido-
grel. The study was prematurely stopped because of
evidence of superiority of anticoagulation. Warfarin re-
duced relative risk of stroke by more than 30%, and was
at least as safe as dual anti-platelet therapy. The BAFTA
study [5] assessed the role of anticoagulation compared
to aspirin alone in elderly patients with atrial fibrillation,
and showed how warfarin halved the risk of stroke with
a similar rate of major hemorrhages. Similar results were
obtained by the previous SPAF trial [6], which found no
difference in overall major bleeding between aspirin and
warfarin. Furthermore, Hylek et al. [7] added informa-
tion on warfarin efficacy. They studied incident ischemic
stroke in a cohort of more than 13,500 patients with
non-valvular atrial fibrillation and clearly demonstrated
that good-quality anticoagulation (e.g. INR of 2 or greater)
significantly reduced the risk of ischemic stroke, its severity
and the risk of death. Aspirin efficacy was no different
from that of poor-quality anticoagulation as far as the risk
of death was concerned.
The influence of anticoagulation control over outcome
was clearly evidenced by White and colleagues [8]. They
reported a clear relationship between the time in thera-
peutic range (TTR) and the risk of death and vascular
events: patients with a TTR less than 60% had higher
rates of annual mortality and major bleeding compared
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ively 4.2% vs 1.69% and 3.85% vs 1.58%; the difference
remained statistically significant also when compared to
patients in moderate control [TTR, 60-75%].
The direct comparison of warfarin to the new oral an-
ticoagulants (NOAs), e.g. dabigatran [9], rivaroxaban
[10] and apixaban [11] outlines the safety profile of these
new drugs, whose main advantage is to reduce intracra-
nial hemorrhage. The NOAs, compared to warfarin, are
also able to significantly reduce by nearly 10% overall
mortality, although such a difference was not statistically
significant in all the studies. In these trials, except in
ROCKET-AF [10] with rivaroxaban, the warfarin whom
the NOAs are compared to is a good quality warfarin
with a 64% TTR. Rivaroxaban and dabigatran 150 mg
bid had the same safety profile of warfarin while apixa-
ban and dabigatran 110 mg bid were safer than warfarin.
Furthermore, apixaban and dabigatran 150 mg bid sig-
nificantly reduced the incidence of stroke and systemic
thromboembolism. Although the new oral anticoagu-
lants homogeneously reduced the risk of intracranial
hemorrhage, rivaroxaban and dabigatran increased the
incidence of gastrointestinal bleeding.
Warfarin in the real life of anticoagulation clinics
The evidence coming from the results of the trials and
meta-analysis aforementioned offers a safe and effective
drug. The variability of warfarin effect, and the wide
spectrum of drug interactions [12], implies frequent
INR monitoring and dose adjustment. The challenging
management of warfarin induced the development of
professionals and clinics, dedicated to anticoagulation
therapy, e.g. the anticoagulation clinics. Furthermore,
algorithms for warfarin dose adjustment, for thrombotic
and hemorrhagic risk, were created in order to help physi-
cians in the anticoagulation management.
Anticoagulation clinics are dedicated to the manage-
ment of anticoagulation, and this enables achievement of
higher TTR; the higher the TTR, the safer the anticoagu-
lation therapy. In 1996, the Italian federation of anticoa-
gulation clinics, FCSA (Federazione Centri Sorveglianza
terapia Anticoagulante), published a prospective cohort
study on 2,745 consecutive patients treated with VKAs,
studied from the start of their oral anticoagulation [13].
They achieved a median TTR of 68%; patients with low
intensity anticoagulation performed an even better TTR,
compared to patients treated with a high-intensity regi-
men. The rate of fatal and major bleedings, among these
patients, was extremely low: respectively 0.25 and 1.1
per 100-patient-years of follow up. The rate of bleeding
was significantly higher in the first 90 days of treatment,
and in elderly patients (≥ 70 years-old). Bleeding rate was
lower in patients who received anticoagulants because of
venous thromboembolism. A more recent report of ItalianFCSA [14] confirmed the safety of warfarin, and the low
rate of major bleedings among elderly patients managed by
anticoagulation clinics: the bleeding rate was 1.87 per 100-
patient-years of follow up, with 0.55 intracranial hemor-
rhages. Nearly one fifth of all bleedings occurred in the first
three months of treatment.
There are few direct comparisons on the quality of TTR
between countries. The existing data addressing this issue
come from the ISAM Study [15]. This was a retrospective,
multi-centre cohort study, enrolling about 1,511 patients,
randomly recruited from representative practices (routine
medical care in the US, Canada, and France; anticoagula-
tion clinics in Italy and Spain). Italy and Spain achieved
higher levels of TTR compared to US, Canada and France.
However, most of the Italian and Spanish patients were
managed in anticoagulation clinics, while patients in the
other countries were mainly managed in routine medical
care. Anticoagulation clinics displayed a higher quality
anticoagulation compared to routine medical care [16].
Anticoagulation clinics employed algorithms to sim-
plify warfarin dose management and computerized algo-
rithms were also validated for clinical use. The group of
the Hamilton General Hospital [17], based on the experi-
ence of Detroit Henry Ford Hospital, formulated a simple
two-step dosing algorithm which allowed a significant
improvement of TTR. The employment of computerized
algorithms [18] guaranteed a faster achievement of the
steady state in the induction phase and the achievement of
a higher TTR in the maintenance phase (71.2% vs 68.2%).
Algorithms including pharmacogenomic data, e.g. poly-
morphisms of VKOR1 and CYP2C9 genes, have proved
more accurate in predicting warfarin dosage [19]. Despite
the demonstration of a more accurate prediction of war-
farin dose, its cost-effectiveness is still debated [20] and
international guidelines still do not suggest routine use of
pharmacogenomics in anticoagulant therapy [21].
In order to simplify the management of anticoagulant
therapy, a number of clinical trials evaluated the use of
patient self-testing (PST) and patient self-management
(PSM). A recent meta-analysis by Bloomfield et al. [22]
included twenty-two studies that enrolled more than
8,400 patients. Fewer than 50% of potentially eligible pa-
tients successfully completed the training and agreed to
be randomly assigned. PST and PSM patients had lower
total mortality (Odd ratio, OR 0.79), lower risk for major
thromboembolism (OR 0.58) and no increased risk for a
major bleeding event. However the greatest pitfall of
these studies is that most of the patients were Caucasian
and most of all had a high level of education, which is
not commonly found in real practice.
Warfarin in real life outside anticoagulation clinics
The majority of patients treated with VKAs are managed
in routine medical care, outside anticoagulation clinics.
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general practitioners, reveals that no more than a third
of all the VKA-treated patients are managed in anticoa-
gulation clinics [23]. This is not a minor issue because
the efficacy and safety of anticoagulation depend on the
management setting. Answell et al. [15] in ISAM study,
highlighted the different performance, in terms of TTR,
between these two settings. Van Walraven and col-
leagues of the Ottawa Health Research Institute [24]
reviewed all published randomized or cohort studies that
measured international normalized ratios (INRs) serially
in VKA treated-patients. This meta-analysis comprised
more than 50,000 patients, most of whom had been
treated in anticoagulation clinics; only 24.4% had been
treated in community practices. The median TTR was
63,6%; the only factors related to TTR were study setting,
self management and drug (acenocoumarol vs warfarin).
TTR in clinical trials was 12.2% higher than that of com-
munity practice and the difference between community
practice and anticoagulation clinics was statistically sig-
nificant with a 8.3% difference in TTR. The patients
treated with warfarin in community practice had a me-
dian TTR of only 50%.
TTR is directly related to outcome [7]. In the ACTIVE
W study [25], clinical benefit was strictly related to time
in therapeutic range. A TTR less than 58% did not allow
to detect any advantage of warfarin over dual anti-
platelet therapy, in terms of clinical efficacy. RE-LY trial,
comparing dabigatran and warfarin in SPAF, clearly
showed how the advantage of dabigatran over warfarin
was directly related to TTR performance [26]. When
TTR was over 72%, dabigatran did not perform any better
than warfarin.
Clinical trials and anticoagulation clinics performances,
in terms of TTR, are hardly reproducible in community
settings. A recently published survey provided us with
an analysis of the Italian landscape [27]. Degli Esposti
et al. analyzed the database of three big local health
agencies, encompassing more than 770,000 persons.
They identified 10,833 patients affected by atrial fibrilla-
tion and treated with VKAs, and measured their adher-
ence to treatment, and the quality of anticoagulation.
Median TTR of naïve patients was 47.9%, while patients
in long-term anticoagulation had a median TTR of
56%. Even the patients in long-term stable therapy, who
displayed a good adherence to warfarin, had a TTR no
higher than 60%.
This poor quality anticoagulation translates into a re-
duced effectiveness. Indeed real practice analysis does
not reproduce the 62% reduction of stroke incidence
observed in Hart’s meta-analysis [1]. Caro et al. [28],
compared Canadian VKA-treated outpatients for SPAF
with patients without any antithrombotic treatment
and observed a dismal 30% reduction of stroke. Darkowand colleagues [29] selected 12,359 patients with atrial
fibrillation from a large healthcare system. More than
61% of these patients did not receive warfarin or VKAs.
The Authors found that the relative risk reduction of vas-
cular events in warfarin-treated patients was 22% as com-
pared to those not treated with warfarin. In a wide group
of Medicare patients, Birman-Deynch et al. [30], ob-
served a 35% relative risk reduction in VKA-treated pa-
tients as compared to those receiving no anti-thrombotic
therapy. These studies should be compared with a similar
real life survey, the ATRIA Study [31], conducted on
13,428 patients, most of whom were treated in anticoagu-
lation clinics. Relative risk reduction was found to be
nearly 50% with a net benefit in overall survival. Al-
though the results of ATRIA Study [31] are not directly
comparable to those of Darkow [29] and of Birman-
Deynch [30], the importance of different setting where
the anticoagulation is managed seems to be evident in
terms of effectiveness.
Real practice differs from clinical trials and from antic-
oagulation clinics also from the safety point of view.
Gomes et al. [32] recently published data regarding the
safety of oral anticoagulant therapy in more than 125,000
patients. The rate of major bleeding in real life was more
than double than that reported in anticoagulation clinics
[13,14]. Bleeding risk was directly proportional to age and
CHADS2 score. Two thirds of bleedings were gastrointes-
tinal, and the fatality rate was 14%, while intracranial hem-
orrhages had a much higher mortality (e.g. 42%). No
difference in TTR was observed between patients with
bleeding and those without.
All these dilemmas and troubles translate into a very
low rate of prescription of VKAs, thus reducing the
benefit of a very powerful therapy. Real life data sur-
veys show that the rate of warfarin prescription is low.
The Euro Heart Survey on Atrial Fibrillation [33], con-
ducted by the European Society of Cardiology, ob-
served a prescription of anticoagulation that was no
higher than 60% and paroxysmal atrial fibrillation was
negatively related to prescription. A recently survey of
Italian Cardiology and Internal Medicines [34], showed
a similar rate of prescription of anticoagulation: ad-
vanced age and paroxysmal atrial fibrillation were
negatively associated to prescription. Waldo et al. [35],
reported a rate of prescription of 55% and found that
advanced age and paroxysmal atrial fibrillation nega-
tively influenced warfarin prescription. Surveys among
general practitioners found an even lower prescription
[36]. Although more than 90% of patients had a moderate
or high risk of stroke, less than one third of these patients
were treated with oral anticoagulants. Furthermore, oral
anticoagulation therapy was “lost in translation” [37]:
after 12 months, only 42% of the patients were still re-
ceiving warfarin and after two years the percentage of
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to 28%.
The two most frequently given reasons against prescrip-
tion, were the risk of falls and a previous hemorrhage.
These elements and the perceived risk of bleeding are two
of the main reasons which explain the discrepancy between
warfarin indication and prescription [38]. As far as the risk
of falls is concerned, more than 20 years ago Man Son
Hing et al. [39] outlined how ephemeral the risk of falls is
and that it should not even be considered during anticoa-
gulation prescription. During these last years a number
of scores have been produced in order to weigh the
hemorrhagic risk. Despite their low sensitivity and specifi-
city [40,41], the European Society of Cardiology advices to
use these scores [42]. A high hemorrhagic risk should not
prevent warfarin prescription but should focus medical
attention on the patient.
An indirect proof of the discrepancy between war-
farin performance in clinical trial and in common prac-
tice comes from the experience with the NOAs in real
world. Both rivaroxaban and dabigatran in clinical trials
were associated with a higher incidence of gastrointes-
tinal hemorrhages as compared to warfarin [9,10]. The
U.S. Food and Drug Administration (FDA) conducted a
survey, called Mini-Sentinel [43], to monitor the bleeding
complications of dabigatran. They recorded the bleed-
ing complications of two matched cohorts of newly
treated patients, by comparing warfarin-treated pa-
tients to dabigatran-treated ones. This survey showed
how, in real life, warfarin caused more bleeding from
the gastrointestinal tract compared to dabigatran. The
rate of gastrointestinal bleeding in dabigatran arm
was similar to that reported in RE-LY; bleeding rate
in warfarin treated patients was higher than that ob-
served in RE-LY. A Danish survey [44], in which
dabigatran-treated subjects with AF were compared
with a propensity-matched cohort of warfarin-treated
patients, confirms the findings of FDA Mini-Sentinel.
Dabigatran gave a 40% reduction in gastrointestinal
bleeding, a 30 to 50% reduction in overall mortality and
furthermore also myocardial infarction was significantly
reduced with dabigatran, in contrast with the findings of
the RE-LY study [9,45]. This effect, rather than being due
to a better performance of dabigatran in real practice,
seems to be related to a worse than expected effect of
warfarin.
Conclusions
From ideal to real: what’s left?
Warfarin and the other VKAs are effective drugs. Al-
though the NOAs are safe and effective, warfarin seems
to ensure, in vitro, a greater suppression of normal
haemostatic mechanisms because of a better inhibition
of thrombin generation [46]. Indeed, such a markedactivity on blood coagulation might be responsible for the
higher incidence of intracranial bleeding and for the appar-
ent better protection from myocardial infarction [47]. In
addition, in the RE-LY study, in the quartile of AF patients
who showed the highest levels of TTR, no advantage of
dabigatran at a dose of 150 mg × 2 could be noticed as
compared to warfarin [25].
Warfarin and VKAs have a unique pharmacokinetic
profile: the variability of their effect requires a close
monitoring and management which led to the devel-
opment of anticoagulation clinics. The effect and the
safety of warfarin is directly proportional to the time
spent in therapeutic range [7] but the higher the TTR
the higher the number of blood tests. The best results
are related to the best quality of anticoagulation [8]
but how many people can achieve the best control?
How many people can be treated by anticoagulation
clinics? There are not much data about this issue
however, it is likely that - at least in Italy - no more
the 30-40% of the VKA-treated patients are managed
in anticoagulation clinics [23]. The quality of therapy
in anticoagulation clinics is comparable to the one we
met in clinical trials however, that is not the case for
the rest of the patients. Median TTR of outpatients is
far from being optimal and only in a few patient we
can hardly get near to a 60% TTR [27].
The management of VKAs requires experience and
dedication. In real life, warfarin has a safety profile
which is very much different from that of the clinical tri-
als [32]: many patients experience bleeding complica-
tions or a wide variability of INR values that often
induce the patient to seek for medical attention. Budnitz
et al. [48], indeed, reported an analysis of hospitalization
and iatrogenic side effects underlining how warfarin use
was associated to a high rate of hospital admittance.
One third of all hospitalizations due to drug side effects
are related to warfarin.
Warfarin and the other VKAs still remain the first and
only available therapy for a sizeable proportion of dis-
eases for which yet no real alternatives are available.
VKAs management is challenging; anticoagulation clinics
offer the safest and most effective management of these
drugs. However, oral anticoagulation therapy is widely
used and anticoagulation clinics cannot take care of all
the patients treated with VKAs. Therefore most of the
patients are managed elsewhere. This obviously translates
into a worse TTR and to a loss of efficacy and safety in
anticoagulant therapy, leading to complications, hospital-
izations and increased mortality. All this turns into cost
increase. The reproducibility of NOAs effect in real life
seems to be promising. The easier management of NOAs
could lead to an increase of use of anticoagulant therapy
and thus to spread stroke prevention and to spare mor-
tality and morbidity.
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characteristics make them hard to handle. Dedicated
professionals should manage them but, also because of
practical issue, where possible, they should be substituted
by drugs whose management and pharmacokinetics are
definitely more plain.
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